Relypsa, Inc. Announces Appointment of John Orwin as CEO
5/16/2013 11:52:41 AM
More...
|
Relypsa, Inc. Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
5/13/2013 10:05:17 AM
More...
|
Relypsa, Inc. Announces Agreement With FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia
1/3/2013 9:30:28 AM
More...
|
Relypsa, Inc. Announces Changes to Board of Directors
1/3/2013 6:50:13 AM
More...
|
Kristine M. Ball Joins Relypsa, Inc. as Senior Vice President, Chief Financial Officer
12/11/2012 11:11:18 AM
More...
|
Relypsa, Inc. Announces $80 Million Private Financing Transaction
8/15/2012 7:29:40 AM
More...
|
Relypsa, Inc. Raises $49.7 Million of $80 Million Funding Round
8/13/2012 8:01:05 AM
More...
|
Lance Berman, M.D. Joins Relypsa, Inc. as Senior Vice President, Commercial Strategy & Medical Affairs
2/8/2012 6:20:53 AM
More...
|
Relypsa, Inc. Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease
6/28/2011 9:38:37 AM
More...
|
Relypsa, Inc. Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting
5/23/2011 7:15:37 AM
More...
|
|